Capes, A., Rossoni, C., Gat, E., Cartron, G., Gros, F.-X., Bachy, E., Manson, G., Brisou, G., Thieblemont, C., Guidez, S., La Rochelle, L. D., Dulery, R., Malard, F., Jardin, F., Tessoulin, B., Le Bras, F., Morschhauser, F., Durand, A., Llorente, C. C., Bories, P., Loschi, M., Choquet, S., Damaj, G.-L., Rubio, M.-T., Tanguy-Schmidt, A., Bay, J.-O., Joris, M., Carras, S., Lebras, L., Abraham, J., Malfuson, J.-V., Fouillet, L., Hermine, O., Chauchet, A., Herbreteau, L., Guffroy, B., Decroocq, J., Le Gouill, S., Houot, R. and Bourbon, E. (2026) “Characterization and impact of response to holding/bridging therapy in second-line large B-cell lymphoma patients treated with axicabtagene ciloleucel: a LYSA study from the French DESCAR-T registry”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2026.301559.